Described are medical graft products, systems, and methods for treating fistulae. Certain products of the invention are configured to have portions residing in and around a primary fistula opening, e.g., one occurring in a wall of the alimentary canal. One such product includes a biocompatible graft body which is configured to block at least the primary opening. The graft body includes a capping member, which is configured to contact portions of the alimentary canal wall adjacent to the primary opening, and an elongate plug member extending from the capping member, which is configured to extend into at least a portion of the fistula. In certain embodiments, a graft body component has the capacity to expand or otherwise change form to provide a suitable capping arrangement. Such a component can include a resilient wire frame, e.g., one that is self-expandable or one that requires at least some manipulation in order to expand.

A method is described for the production of hybrid structures formed by the coupling of nanofibrous parts and microfibrous parts made with silk fibroin, possibly hierarchically organized into complex structures comprising more than two of said parts; these hybrid structures are used as implantable biomedical devices with tailored biological, geometrical and structural features, such that they can be adapted to different application requirements in the field of regenerative medicine.

A method for preparing a biological material for implanting provides irradiating at least a portion of the surface of the material with an accelerated Neutral Beam.

The present disclosure features adhesive compositions and methods of use thereof related to the medical, veterinary, and dental fields.

The present disclosure provides tissue products produced from adipose tissues, as well as methods for producing such tissue products. The tissue products can include acellular tissue matrices for treatment of a breast.

A technique can consistently achieve thicknesses of ≤50 μm for corneal tissue for Descemet stripping automated endothelial keratoplasty (DSAEK). Grafts with thicknesses of ≤50 μm are also known as nanothin DSAEK (NT-DSAEK) grafts. Evidence shows that using thinner DSAEK grafts, particularly NT-DSAEK grafts, can significantly improve visual outcomes. According to an example embodiment, a method for producing a corneal graft includes drying a donor cornea to cause a pre-cut thickness of the donor cornea to decrease. The method includes, concurrently with drying the donor cornea, determining pre-cut thickness measurements for the donor cornea. The method includes, in response to the pre-cut thickness measurements indicating the pre-cut thickness of the donor cornea has decreased to a predetermined value, cutting the donor cornea to a post-cut thickness of ≤100 μm, or more particularly ≤50 μm, to produce a corneal graft.

A method and system for making a bone plug using cortical bone material. A patient jaw having insufficient bone at a surgical site may be scanned to provide a 3D image which may be used to design a virtual bone plug and to fabricate the bone plug for placement within the patient. The bone plug may be formed from cortical bone that can be reconstituted and demineralized or demineralized and milled to shape.

The invention provides a method for producing a cell aggregate containing a ciliary marginal zone-like structure by culturing a cell aggregate containing a retinal tissue in which Chx10 positive cells are present in a proportion of 20% or more of the tissue in a serum-free medium or serum-containing medium, each containing a substance acting on the Wnt signal pathway for only a period before the appearance of a RPE65 gene expressing cell, followed by culturing the “cell aggregate in which a RPE65 gene expressing cell does not appear” thus obtained in a serum-free medium or serum-containing medium, each not containing a substance acting on the Wnt signal pathway and so on.

The invention provides a method for inducing gelation and biomimetic mineralization of a silk fibroin solution by alkaline phosphatase. A micromolecular polypeptide that is sensitive to ALP and has good biocompatibility and self-assembly property is introduced as a gelator precursor, which can remove a phosphate group under the catalytic action of ALP to generate NY, to trigger supramolecular self-assembly, and therefore SF co-self-assembly is synergistically induced, finally resulting in rapid formation of SF hydrogel. ALP wrapped in an SF-NY hydrogel network still retains its catalytic activity and catalyzes beta-glycerophosphate to release free phosphate ions, so that formation of apatite minerals is induced in the gel. The biomimetic mineralized SF gel can be used as a biomimetic scaffold to promote the adhesion, proliferation and osteogenic differentiation of rat bone marrow mesenchymal stem cells in vitro, and can also promote the natural healing of femoral defects in a rat model.

Disclosed herein are nerve xenografts and methods of using such for repairing and/or protecting a nerve tissue in a human patient. The subject matter disclosed herein generally relates to nerve xenografts derived from genetically engineered source animals, and use of such nerve xenografts for repairing and/protecting nerve tissue in a human patient, e.g., for reconstruction of large peripheral nerve gaps, treatment of spinal cord injuries and ailments, and other therapies.